Mountain Pacific Investment Advisers Inc. ID cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 4.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,438 shares of the company’s stock after selling 900 shares during the quarter. Mountain Pacific Investment Advisers Inc. ID’s holdings in AbbVie were worth $2,938,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of ABBV. Goepper Burkhardt LLC boosted its stake in shares of AbbVie by 1.9% in the fourth quarter. Goepper Burkhardt LLC now owns 3,506 shares of the company’s stock valued at $567,000 after buying an additional 67 shares during the period. Naviter Wealth LLC lifted its position in AbbVie by 0.9% during the first quarter. Naviter Wealth LLC now owns 7,378 shares of the company’s stock worth $1,176,000 after purchasing an additional 68 shares during the period. Delta Financial Group Inc. grew its stake in AbbVie by 1.2% during the first quarter. Delta Financial Group Inc. now owns 5,757 shares of the company’s stock worth $917,000 after buying an additional 68 shares in the last quarter. Sand Hill Global Advisors LLC increased its holdings in AbbVie by 0.4% in the 1st quarter. Sand Hill Global Advisors LLC now owns 18,755 shares of the company’s stock valued at $2,989,000 after buying an additional 68 shares during the period. Finally, Kistler Tiffany Companies LLC raised its position in shares of AbbVie by 0.6% in the 1st quarter. Kistler Tiffany Companies LLC now owns 12,314 shares of the company’s stock valued at $1,963,000 after buying an additional 70 shares in the last quarter. 67.86% of the stock is currently owned by hedge funds and other institutional investors.
In other AbbVie news, CEO Richard A. Gonzalez sold 18,500 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the transaction, the chief executive officer now directly owns 625,294 shares of the company’s stock, valued at approximately $93,262,600.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.26% of the company’s stock.
Analysts Set New Price Targets
AbbVie Price Performance
ABBV stock traded up $0.46 during mid-day trading on Wednesday, hitting $149.73. 297,630 shares of the stock were exchanged, compared to its average volume of 5,633,344. The company has a debt-to-equity ratio of 4.33, a current ratio of 0.89 and a quick ratio of 0.77. The stock has a market capitalization of $264.28 billion, a price-to-earnings ratio of 30.72, a PEG ratio of 2.70 and a beta of 0.58. The business has a fifty day moving average price of $145.49 and a 200 day moving average price of $147.49. AbbVie Inc. has a 12 month low of $130.96 and a 12 month high of $168.11.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Thursday, July 27th. The company reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.12. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. The firm had revenue of $13.87 billion for the quarter, compared to analysts’ expectations of $13.52 billion. On average, sell-side analysts anticipate that AbbVie Inc. will post 11.03 EPS for the current year.
AbbVie Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a dividend of $1.48 per share. This represents a $5.92 dividend on an annualized basis and a yield of 3.95%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s payout ratio is 121.81%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.
- Five stocks we like better than AbbVie
- Energy and Oil Stocks Explained
- 3 Reasons Dollar General Shares Belong in the Shopping Cart
- Stock Sentiment Analysis: How it Works
- Shell’s 4.12% Dividend Yield: An Attractive Feature for Investors
- Industrial Products Stocks Investing
- Apple Shares Stumble Into The Buy Zone
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.